<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the paroxetine and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEBIVOLOL" rxcui="31555">
<ATC code="C07AB12" />
<ATC code="C07BB12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>C0NTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RISPERIDONE" rxcui="35636">
<ATC code="N05AX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, adjustment of the dosage of the risperidone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the paroxetine and after it is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
